Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Daniel J. Renouf,Jonathan M. Loree,Jennifer J. Knox,Petr Kavan,Derek J. Jonker,Stephen Welch,Felix Couture,Frédéric Lemay,Mustapha Tehfe,Mohammed Harb,Nathalie Aucoin,Yoo Joung Ko,Patricia A. Tang,James T. Topham,Shidong Jia,Pan Du,David F. Schaeffer,Sharlene Gill,Dongsheng Tu,Christopher J. OCallaghan

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

2021

4135Background: PA.7 evaluated whether combining PD-L1 and CTLA-4 inhibition with GEM and Nab-P increases efficacy. A previous analysis of the PA.7 data demonstrated high plasma based TMB (≥9 mut/M...

Keywords:

Medicine
Gemcitabine
Tremelimumab
Germline
Cancer research
Nab-paclitaxel
predictive value
pancreatic ductal adenocarcinoma
first line therapy
Durvalumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations